CALL FOR ABSTRACTS

- **Abstract Submission Deadline:** November 19, 2020
- **Late-Breaking and Clinical Trials**
  - **Abstract Submission Deadline:** January 11, 2021

Continuing Medical Education Activity -
AMA PRA Category 1 Credits™ available

AACR.ORG ★ #AACR21

ANNUAL MEETING

2021

VIRTUAL ★ #AACR21

DISCOVERY SCIENCE

DRIVING CLINICAL BREAKTHROUGHS
TABLE OF CONTENTS

2     Key Dates
3     Welcome
4     Scientific Program
     Plenary Sessions
     Major Symposia
     Advances Sessions
     Forums
     Educational Program

8     Policy Sessions
9     Spotlight on Clinical Trials
10    Professional Advancement Opportunities
11    Continuing Medical Education (CME)
12    Survivor and Patient Advocacy Program
13    Press Coverage and Social Media
14    Support for Attendance
16    Guidelines for Preparation and Submission of Abstracts
19    Abstract Categories
24    AACR Membership Opportunities
26    General Information
28    Annual Meeting Committees

ABOUT THE COVER IMAGE:
©2020 American Association for Cancer Research
Inside of sphere (clockwise): AACR Virtual Special Conference: Epigenetics and Metabolism art; Glioblastoma (iStock); DNA sequencing (Getty)
Foreground of sphere (clockwise): 3D render of T cells attacking cancer cells (Getty); 3D illustration of a method of DNA sequencing (Getty); Medical 3D illustration of a dividing cancer cell (Getty)
September 30, 2020  Abstract Submission Opens

October 13, 2020  Application Deadline: NextGen Stars

November 12, 2020  Membership Application Deadline for Regular Abstract Sponsors and Scholar-in-Training Award Applicants

November 19, 2020  Regular Abstract Submission Deadline (11:59 p.m. ET)

November 19, 2020  Application Deadlines:
AACR Global Scholar-in-Training Awards
AACR Minority-Serving Institution Faculty Scholar in Cancer Research Awards
AACR Minority Scholar in Cancer Research Awards
AACR Scholar-in-Training Awards
AACR Women in Cancer Research Scholar Awards

December 18, 2020  Late-Breaking and Clinical Trials Abstract Submission Opens

January 6, 2021  Online Itinerary Planner Available

January 7, 2021  Membership Application Deadline for Late-Breaking and Clinical Trials Abstract Sponsors

January 11, 2021  Late-Breaking and Clinical Trials Abstract Submission Deadline (11:59 p.m. ET)

February 1, 2021  Regular Abstract Status Notifications Sent

February 4, 2021  Submission Deadline: Final Data for Clinical Trial Placeholder Abstracts

February 10, 2021  Late-Breaking and Clinical Trials Abstract Notifications Sent

February 22, 2021  Regular Abstract Withdrawal Deadline

March 9, 2021  Late-Breaking and Clinical Trials Abstract Withdrawal Deadline
Dear Members and Friends of the AACR,

We are pleased to announce the Call for Abstracts for the 112th Annual Meeting of the American Association for Cancer Research (AACR). Reflecting the theme of this year’s meeting, “Discovery Science Driving Clinical Breakthroughs,” the scientific program will span the broad spectrum of cancer science and medicine from basic, translational, and clinical research including cancer health disparities; to early detection, interception, prevention, and population science; to regulatory science and policy.

The Opening Plenary Session will address the theme of the meeting and will include presentations on lineage tracing of tumor metastasis, tumor metabolism, genomic sequencing in diverse populations, immune surveillance, antitumor immune response, and clinical implications. New this year is the Discovery Science Plenary Session, which will focus on the mechanisms, impact, and exploitation of cancer chromosomal instability for potential therapeutic intervention. Also, a comprehensive educational program of more than 60 educational sessions and methods workshops, covering a wide array of disciplines and new technologies, is currently under development.

Major progress against cancer has been realized over the past few decades due to remarkable scientific advances and multidisciplinary collaborations, and during this year a record number of new cancer treatments were approved by the U.S. Food and Drug Administration. However, during the COVID-19 pandemic, many labs were forced to close, and clinics have needed to shift resources and refocus efforts to combat this enormous public health crisis. There is now much concern that the delays in cancer screening, diagnosis, and treatment because of the COVID-19 pandemic will have a significant negative impact on the pace of progress against cancer and on cancer patient outcomes. Now more than ever it is critically important to focus our collective efforts and resources on our mission to prevent and cure all cancers.

Despite these challenges, this has been a transformative year for the global cancer research community – one that has resulted in a new wave of scientific innovation that will be reflected in our Annual Meeting program. The year 2021 will be an exciting time for us to celebrate the 50th Anniversary of the signing of the National Cancer Act. The signing of this Act was a pivotal moment in history, as it has led to the formation of highly impactful comprehensive cancer centers in the U.S., the development of education and training programs for early-career laboratory and clinical investigators, increased funding for innovative cancer research, and many cancer breakthroughs that have saved millions of lives from the disease.

Proffered oral and poster presentations selected from submitted abstracts are a vital part of our Annual Meeting. For your interest, a new abstract category for research on COVID-19 and cancer has been added to our Call for Abstracts. We look forward to receiving your submissions and to providing an interactive venue for you to share your important work. Your participation in the 2021 Annual Meeting will not only be a welcome addition to the program, but it will also maximize collaborations, stimulate creative thinking about how to accelerate progress against cancer, and contribute greatly to the cause.

The regular abstract deadline is November 19, 2020. Our proffered program also features special oral presentation opportunities in several Clinical Trial Plenary Sessions for abstracts reporting on high-impact clinical trials. The deadline for late-breaking abstracts and clinical trial abstracts is January 11, 2021.

Please note that recently, the AACR Board of Directors approved an expansion of the abstract sponsorship privileges for certain AACR member types. We encourage AACR members to use their additional privileges to sponsor abstract submissions from their mentees and nonmember colleagues. Please view the details of these expanded privileges on page 18.

During these difficult times our heartfelt sympathies are extended to everyone who has been impacted by this global health crisis. It is our sincere hope that you join us virtually in 2021 to discuss your innovative work across the full spectrum of cancer research.

We look forward to receiving your abstract submissions and to your active participation in AACR Annual Meeting 2021. With best wishes and regards,

Antoni Ribas, MD, PhD, FAACR  Charles Swanton, FRCP, BSc, PhD, FAACR
President, 2020-2021  Chair, 2021 Program Committee
WHY YOU SHOULD PARTICIPATE IN THE WORLD’S MOST IMPORTANT CANCER RESEARCH MEETING

The AACR Annual Meeting highlights the work of the greatest minds in cancer science and medicine from institutions all over the world. This meeting presents the many scientific discoveries across the breadth of cancer research—from prevention, early detection, and interception; to cancer biology and genetics, translational, and clinical studies; to survivorship, population science, and advocacy. You will be exposed to the latest developments in all areas of cancer research, form new collaborations, and learn how to apply exciting new concepts, tools, and techniques to your own research.

This year’s program, with the theme of “Discovery Science Driving Clinical Breakthroughs,” will be a comprehensive, cutting-edge scientific event that you will not want to miss!

PROGRAM IN PROGRESS

The Annual Meeting will include a comprehensive educational program comprised of Educational Sessions and Methods Workshops. In addition to the Opening Ceremony, Opening Plenary, and other thematic Plenary Sessions, a new and exciting Discovery Science Plenary Session will be open to all registrants. Abstracts submitted for the regular (November 19, 2020) or late-breaking and clinical trials (January 11, 2021) submission deadlines will be considered for short talks or ePoster presentations. The 2021 Program in Progress follows; additional exciting and timely invited sessions are being developed and will be posted at AACR.org/AACR2021.

PLENARY SESSIONS

DISCOVERY SCIENCE PLENARY SESSION: MECHANISMS, IMPACT, AND EXPLOITATION OF CANCER CHROMOSOMAL INSTABILITY

David Pellman, Dana-Farber Cancer Institute, Boston, MA
Angelika Amon, Massachusetts Institute of Technology, Cambridge, MA
Stephen P. Jackson, University of Cambridge, Cambridge, United Kingdom
Karlene A. Cimprich, Stanford University, Stanford, CA

OPENING PLENARY SESSION: DISCOVERY SCIENCE DRIVING CLINICAL BREAKTHROUGHS

Chair: Charles Swanton, The Francis Crick Institute, London, United Kingdom
Jonathan S. Weissman, Whitehead Institute, Cambridge, MA
Karen H. Vousden, The Francis Crick Institute, London, United Kingdom
Matthew G. Vander Heiden, Massachusetts Institute of Technology, Cambridge, MA
Melissa B. Davis, Weill Cornell Medical College, New York, NY
Mark A. Dawson, Peter MacCallum Cancer Centre, Melbourne, Australia
Zhijan James Chen, UT Southwestern Medical School, Dallas, TX

UNDERSTANDING THE MOLECULAR AND MICROENVIRONMENTAL DETERMINANTS OF CANCER

Chair: Christina Curtis, Stanford University, Stanford, CA
Garry P. Nolan, Stanford University School of Medicine, Stanford, CA
Serena Nik-Zainal, University of Cambridge, Cambridge, United Kingdom
Ross L. Levine, Memorial Sloan Kettering Cancer Center, New York, NY
Jérôme Galon, INSERM, Paris, France
AACR ANNUAL MEETING 2021
SCIENTIFIC PROGRAM
Plenary Sessions (cont’d)

CANCER BIOLOGY AND THE CHANGING THERAPEUTIC LANDSCAPE
Chair: Sheila A. Stewart, Washington University, St. Louis, MO
Tony Hunter, Salk Institute, La Jolla, CA
William G. Kaelin, Jr., Dana-Farber Cancer Institute, Boston, MA
Olufunmilayo I. Olopade, University of Chicago Medicine Comprehensive Cancer Center, Chicago, IL
Dennis J. Slamon, UCLA David Geffen School of Medicine, Los Angeles, CA

LEVERAGING THE IMMUNE SYSTEM IN THE WAR ON CANCER
Chair: Nina Bhardwaj, Icahn School of Medicine at Mount Sinai, New York, NY
Anjana Rao, La Jolla Institute for Immunology, La Jolla, CA
Sergio A. Quezada, University College London Cancer Institute, London, United Kingdom
Michel Sadelain, Memorial Sloan Kettering Cancer Center, New York, NY
Ignacio Melero, University of Navarra, Pamplona, Spain

MAJOR SYMPOSIA
AACR-Bayard D. Clarkson Symposium on Stem Cells, Leukemia, and the Niche
Advances in Cancer Nanotechnology
Alternative DNA Repair Pathways and Their Drug Targets
Artificial Intelligence in Cancer Imaging
Artificial Intelligence/Machine Learning in Cancer Research and Care: Progress and Opportunities
Cancer Immunometabolism
Colorectal Cancer Interception: Immunologic and Pharmacologic Advances
COVID-19 and Cancer Research
Cytokine Receptors in Immuno-oncology: Discovery, Analysis, and Modulation
Deubiquitylating Enzymes as Targets for Cancer Therapy
Developing Rational Combinations of Targeted Drugs
Diet, Clock, and Cancer
Drugging KRAS
Engineering and Modulating Natural Killer Cells for Cancer Immunotherapy
Familial Predisposition: Precision Medicine and Targeted Therapy
From ’Omics Data to Prognostic and Predictive Biomarkers
Functional Precision Medicine in Cancer
Germline Influence on Immunotherapy Outcomes
Implications of Clonal Hematopoiesis in Human Health
Improving Therapy through Normalization of the Tumor Microenvironment
Matrix, Exosomes, and TME Cells in the Metastatic Niche
Mechanisms and Biomarkers of Response and Resistance to Immunotherapy
Metabolism and Chromatin Deregulation in Cancer and Cancer Heterogeneity
Modeling Metastatic Progression in the Mouse
Molecular Imaging
Neoadjuvant Immunotherapy for Melanoma and Other Cancers
New Approaches to Chimeric Antigen Receptor Engineering
New Combinations of Targeted Therapies and Immunotherapies
Next Frontiers in Adjuvant Therapy
Next-Generation Epigenetic Drugs
Options and Opportunities for Treating Metastasis
Paracrine Signaling in Cancer
Phase Separation, Transcription, and Cancer
Progress from Personalized Cancer Vaccine Trials
T Cells in Cancer
The Cancer Dependency Map
The Clinical Proteomic Tumor Analysis Consortium: Building a Proteogenomic Atlas of Cancer
The Microbiome in Cancer Therapy: Hype or Hope?
The Tumor Microbiome and Its Role in Oncogenesis and Modulating Therapy Response
Toward Engineering of Neoantigen-Specific T-Cell Therapies
Tumor Cell Plasticity and Resistance to Cancer Therapies
Tumor Hypoxia and Genetic Instability: New Mechanisms and New Targets
When Is Transforming Growth Factor Beta Targetable?
AACR-ASCO Joint Session: Targets in the Treatment of Renal Cell Cancer
AACR-CSCO Joint Symposium: Single-Cell Analysis—Changing the Landscape of Cancer Research
AACR-JCA Joint Session: Tracking Tumor Evolutionary Dynamics: From Initiation through Metastasis
AACR-ONS Special Session: Symptom Science

ADVANCES IN DIAGNOSTICS AND THERAPEUTICS
Advances in Drug Delivery
Computational Methods for Immunogenomics and Precision Oncology
Diagnostic Tests for Immunotherapy: Current CLIA Lab Testing and Future Directions
DNA Damage Response (DDR) Treatment: Evolving Diagnostic Approaches, Understanding of Replication Stress, and Resistance Mechanisms to DDR Targeting Therapies
Hybrid Technologies for Cancer Imaging, Theranostics, and Image-Guided Interventions
Management of Toxicity of Immune Cell Therapy
Noninvasive Monitoring of Minimal Residual Disease with Liquid Biopsies: Toward Real-Time Treatment Decision-Making
Proton Therapy and FLASH Irradiation
Targeting Transcriptional Cyclin-Dependent Kinases in Cancer
Translational Canine Models Advancing Immunotherapy and Immunogenomics
Understanding and Overcoming Resistance to Third Generation EGFR and ALK Inhibitors

ADVANCES IN ORGAN SITE RESEARCH
Advances in Endometrial Cancer
Advances in Sarcoma Therapy
Developing More Effective Treatments for Triple-Negative Breast Cancer
Diffuse Large B-Cell Lymphoma
Emerging Concepts in Liver Cancer Research
Next-Generation Treatments for Melanoma: Building on Success
Pathways to Early Detection of Pancreatic Cancer
Solid Tumor Brain Metastasis
Targeting Signaling Pathways in Colorectal Cancer
Therapeutic Advances in Biliary Tract Cancers
Therapeutic Vulnerabilities and Resistance Mechanisms in Estrogen Receptor-Positive Breast Cancer

ADVANCES IN PREVENTION, EARLY DETECTION, AND INTERCEPTION
Connecting the Tumor Microenvironment with the Macroenvironment in Cancer Cachexia
Interception of Preneoplasia
Molecular Targets of Precision Prevention and Interception
Panel on Rural Cancer Control
Radiation-Induced Cancers and Cancer Survivorship

ADVANCES IN THE SCIENCE OF CANCER HEALTH DISPARITIES
Carcinogenic Exposures and Global Cancer Prevention
Pan-Cancer Distinctions in Tumor Biology across Ethnicity and Genetic Ancestry
Precision Medicine in Underserved Populations
FORUMS
Are Antitumor T Cells Exhausted or Dysfunctional? Does It Matter?
Are There Cancer Stem Cells?
Biostatistics Debate: Should Science Be Guided by P-Values?
Cancer Cell Dormancy: The Current Paradigm and the Challenges Ahead to Develop New Therapies
CAR T-Cell Therapy or T-Cell Engager?
Data Science and Machine Learning: Will They Revolutionize Cancer Cure and Research?
Embracing Entrepreneurship in Cancer Research
Microbiome Pandemonium: Checkpoints and the Microbiome
Patient-Derived Models for Cancer
The Myths and Realities of the Abscopal Effects
What Is the Role for Oncolytic Viruses in Cancer Treatment?

EDUCATIONAL PROGRAM: EDUCATIONAL SESSIONS AND METHODS WORKSHOPS

The Educational Program is an integral part of the meeting and provides attendees with an opportunity to expand their knowledge base. The Educational Program consists of more than 65 unique sessions covering all areas of cancer research, including the popular multisession programs noted below. More information about the Educational Program will be available at AACR.org/AACR2021.

★ Tumor Immunology and Immunotherapy for Nonimmunologists. Annually, this two-part series combines a comprehensive review of a hot topic in the field with a networking session that enables attendees to participate in group discussions with leading experts in the field.

★ Chemistry to the Clinic. This three-part series provides attendees with foundational knowledge of critical elements of the drug development process, such as lead optimization, identification of targets, and drug modalities.

★ Clinical Trial Design. Over the course of three consecutive sessions, this Methods Workshop will provide attendees with a historical and methodologic understanding of clinical trials and demonstrate how to design an appropriate trial to answer the scientific questions presented by emerging treatments.

Additional details will be posted at AACR.org/AACR2021.
Decisions made by policymakers in Washington, DC, have a direct impact on cancer research and the progress being made against cancer in the United States and throughout the world. The AACR sponsors sessions with policymakers, academic researchers, patient advocates, cancer survivors, and industry representatives to foster dialogue about emerging topics in science and health policy, and regulatory science and policy.

The **Science and Health Policy Track** includes sessions that will provide attendees with an opportunity to learn about how policy impacts science and vice versa. Science policy sessions will examine the current political environment affecting federal funding for the NIH and NCI, including highlighting ways for scientists to get involved in advocating for robust, sustained, and predictable budget increases. Health policy sessions will explore how scientific evidence can inform policy on cancer prevention and control and what impact policies are having on patients and communities. Past health policy sessions have covered topics such as e-cigarettes and tobacco control measures, the Affordable Care Act, and ways to prevent and control pathogen-related cancers, such as increasing the use of the human papillomavirus (HPV) vaccine.

The **Regulatory Science and Policy Track** includes informative sessions designed to highlight recent regulatory developments and provide an open forum for the consideration of issues that the FDA faces as the agency seeks to accelerate the pace of approval of safe and effective treatments for patients with cancer. These sessions offer an opportunity for attendees to discuss cutting-edge issues in cancer drug, biologic, and diagnostic regulation with stakeholders from academia, industry, advocacy, and government. Past regulatory science and policy topics have included strategies for increasing participation of underrepresented populations in clinical trials, guidance for using real-world evidence to support clinical trials during the COVID-19 pandemic, regulatory considerations for developing liquid biopsy tests, implications of site-agnostic therapy approval for drug development, and applications for artificial intelligence/machine learning in regulatory decision-making.

The **Science of Survivorship Track** includes sessions highlighting new and high-value areas of research to address the array of challenges facing long-term cancer survivors. Sessions invite trans-sector discussion among the survivor and advocacy communities, basic and clinical researchers, industry representatives, health care providers, and government officials. Past science of survivorship topics have included aging and cancer, long-term survivorship and vulnerable populations, development of new survivorship models, patient-reported outcomes, data sharing, and patient engagement.
SUBMIT YOUR CLINICAL TRIALS ABSTRACTS TO THE AACR ANNUAL MEETING 2021

Become a part of our growing clinical research program at the Annual Meeting and help us showcase how discovery science continues to transform the lives of cancer patients.

WHY YOU SHOULD SUBMIT

★ Numerous and unique oral presentation opportunities
  • Four Clinical Trials Plenary Sessions offering companion presentations discussing the science behind the trials presented
  • Three Clinical Trials Minisymposia
★ Poster presentations (enhanced e-Posters with opportunities for engagement)
★ Opportunities for extensive national media coverage through the AACR press program
★ Opportunities to simultaneously present your work and publish a manuscript in a high-impact AACR journal
  • Indicate your intention to submit a manuscript during the abstract submission process.
  • Contact pubs@aacr.org with any questions.
★ No restrictions on presenters if the presentation is CME-compliant

WHAT TO SUBMIT

★ Any phase (I, II, III, or any combination) abstract from national or international clinical trials
★ Promising ongoing trials, or unique trial designs that have not yet yielded results, to the Clinical Trials in Progress category (CT08)
★ Encore clinical trials presentations that have been presented solely in abstract form, including publication in conference proceedings. Submissions must include significant additional data from the previous presentation (as determined by the review committee).
★ COVID-19 and cancer clinical trials to the COVID-19 and Cancer (COVID06) or Clinical Trials (CT07) categories.
★ See pages 21-22 for clinical trials (CT) abstract categories and visit AACR.org/AACR2021 for submission guidelines.

WHEN TO SUBMIT

★ Submit your completed or placeholder abstract(s) by the January 11, 2021 deadline for clinical trials and late-breaking abstracts. The clinical trials (CT) abstract categories will not be available for submissions for the November 19, 2020 deadline.
★ Final results and conclusions for placeholder abstracts are due by February 4, 2021.

AACR VIRTUAL ANNUAL MEETINGS I AND II 2020

30 TRIALS IN CLINICAL PLENARY SESSIONS
104 TRIALS IN POSTER SESSIONS
50 TRIALS IN PROGRESS IN POSTER SESSIONS
In support of its mission to promote the education and training of cancer scientists and clinicians and to cultivate a highly skilled and diverse cancer research workforce, the AACR provides Annual Meeting attendees at all career stages—from high school and undergraduate students to senior investigators—with opportunities to enhance and advance their careers. For more information about any of the professional development opportunities that follow, visit AACR.org/AACR2021 and click on the “Professional Development Opportunities” tab.

**NEXTGEN STARS**

Early-career scientists can apply to give a presentation in a Major Symposium or Advances Session at the AACR Annual Meeting 2021. Speaking slots are limited and are only available to AACR Associate Members and to AACR Active Members who are not above the level of assistant professor or equivalent. The NextGen Stars program provides an exciting opportunity to increase the visibility of early-career scientists at the AACR Annual Meeting and to support the professional development and advancement of those selected to speak.

The deadline to submit applications was **12:00 p.m. U.S. ET, October 13, 2020.** Applications consist of an extended abstract (limit 8,000 characters), a CV, and a letter of recommendation from a P.I., department head, or another mentor who is familiar with the applicant’s work. Applicants selected as NextGen Stars for 2021 will receive travel support and complimentary registration for the meeting. Details can be found at AACR.org/AACR2021 under the “NextGen Stars” tab.

**PROFESSIONAL ADVANCEMENT SESSIONS**

*Exclusive Member Benefit*

Professional Advancement Sessions have long been an integral part of the AACR Annual Meeting experience, representing the AACR’s dedication to the education, training, and career advancement of cancer research investigators at all stages of their careers. Each year, several interactive and engaging professional development and career advancement opportunities are organized to provide important skills to investigators at all levels, from students to senior faculty.

All Professional Advancement Sessions are free and exclusive to AACR members. There is no cost to join the AACR as a Student Member (high school students and undergraduates) or Associate Member (graduate students, medical students and residents, and clinical and postdoctoral fellows who are enrolled in education or training programs that could lead to a career in cancer research). If you are not an AACR member, you are strongly encouraged to join and take advantage of being able to attend these sessions and the many other benefits of membership, including the privilege of sponsoring abstracts, and reduced member registration rates for the Annual Meeting 2021. Visit AACR.org/Membership to apply today!

Professional Advancement Sessions to be held at the Annual Meeting 2021 will be announced in the fall. Visit AACR.org/PAS for session updates, including opportunities for physician-scientists and early-career and early-stage investigators.
The AACR’s Continuing Medical Education (CME) Program brings the latest cancer research from “bench to bedside and back.” The AACR has been awarded Accreditation with Commendation status by the Accreditation Council for Continuing Medical Education (ACCME). The AACR CME Program consists of educational interventions designed to encourage the analysis and discussion of the latest findings in all areas of basic, translational, and clinical cancer research not only among researchers, but also by engaging clinicians in this scientific discourse. The AACR is committed to advancing the ability of clinicians to apply critical aspects of cancer research to the clinical practice of oncology to aid in the detection, diagnosis, treatment, and prevention of cancer. The AACR Annual Meeting 2021 will be a Continuing Medical Education Activity and **AMA PRA Category 1 Credits™** will be available. This is a great opportunity to complete your required credit hours.

**MEET YOUR MOC POINT REQUIREMENTS**

If you are a physician, you can meet your Maintenance of Certification (MOC) point requirements at the AACR Annual Meeting 2021. The meeting is CME/MOC accredited. Successful completion of the CME activity enables you to earn MOC points of the American Board of Internal Medicine’s (ABIM) Maintenance of Certification program.
AACR’S COMMITMENT TO SURVIVORS AND PATIENT ADVOCATES

The voices of patients with cancer have never been more important than in today’s environment, especially as patients are partnering with researchers by selflessly donating tissue and personal data to advance progress. Additionally, patient advocates play a crucial role in educating the public about new research discoveries, serving on committees and panels to inform cancer research and regulatory policies, increasing awareness among legislators, and raising precious funds for cancer research.

The AACR recognizes and celebrates the contributions of survivors and patient advocates to cancer research and policy and welcomes their attendance and participation at the AACR Annual Meeting.

Discounted registration rates are available for patient advocates.

AACR SCIENTIST↔SURVIVOR PROGRAM

A special advocacy program that the AACR hosts each year is the AACR Scientist↔Survivor Program (SSP), which is now in its 23rd year. Led admirably since its inception by Anna D. Barker, PhD, of the Lawrence J. Ellison Institute for Transformative Medicine of USC, SSP is designed to build enduring partnerships among the leaders of the scientific, cancer survivor, and patient advocacy communities worldwide. The program has a competitive application process and occurs twice each year, with the larger program being held in conjunction with the AACR Annual Meeting.

This unique program provides an opportunity for patient advocates to learn about cancer research and to interact with scientists, physicians, health care professionals, and other advocates.

Specifically, patient advocate representatives come together to discuss the latest findings in cancer research, foster collaborative interdisciplinary partnerships, and promote progress in new research areas in the cancer field. Advocates benefit from special scientific lectures in lay terms; stimulating small group discussions; and other opportunities to exchange information on key aspects of cancer research, survivorship, advocacy, and public policy.

If you are interested in applying for this year’s SSP, please visit AACR.org/SSP2021 or contact us at advocacy@aacr.org.

Patient advocates can also engage with the AACR in many ways throughout the year, including through AACR’s magazine Cancer Today, the AACR Foundation, the annual AACR Cancer Progress Report, and by participating in advocacy days on Capitol Hill.
ATTRACTING JOURNALISTS WORLDWIDE, GENERATING MAJOR NEWS COVERAGE

The AACR is the authoritative resource and voice for cancer research, and the AACR Annual Meeting garners the best in national and international news coverage. The AACR Virtual Annual Meetings I and II, held in April and June 2020, attracted a total of 174 registered reporters. The two meetings showcased innovative clinical, translational, and basic research and generated nearly 2,500 media clips in leading consumer and trade outlets including The Associated Press, The New York Times, The Washington Post, Reuters, STAT, and Science, among many others.

All abstracts accepted for presentation at the meeting will be considered for inclusion in the official AACR Annual Meeting 2021 press program. For more information on the AACR Annual Meeting press program, please contact Julia Gunther at julia.gunther@aacr.org or Rick Buck at rick.buck@aacr.org.

UTILIZING SOCIAL MEDIA TO AMPLIFY THE CONVERSATION

The AACR Virtual Annual Meetings I and II 2020 also generated significant social media activity in the cancer research community. Social media highlights included:

**AACR Virtual Annual Meeting I 2020:**

- 2,758 people joining the conversation on Twitter
- 9,003 total tweets using the #AACR20 hashtag
- 45,427,000 total impressions

**AACR Virtual Annual Meeting II 2020:**

- 2,307 people joining the conversation on Twitter
- 7,065 total tweets using the #AACR20 hashtag
- 42,426,000 total impressions
Through the generosity of its loyal supporters and grants from the National Cancer Institute (NCI), the AACR is pleased to provide support to meritorious undergraduate students and early-career scientists residing anywhere in the world, and also to members of minority groups residing in the United States and Canada that have been traditionally underrepresented in cancer research and biomedical science, to assist them in attending the AACR Annual Meeting. Detailed information about these award programs, including eligibility and selection criteria, can be found by visiting AACR.org/AACR2021 and clicking on the "Financial Support for Attendance" link.

AACR SCHOLAR-IN-TRAINING AWARDS

**Exclusive Member Benefit**

Scholar-in-Training Awards are available for Associate Members in good standing who are the presenters of meritorious abstracts at the AACR Annual Meeting. These awards are made possible by the generosity of supporting foundations and corporations. Nonmember graduate students, medical students and residents, clinical fellows or equivalent, and postdoctoral fellows who wish to apply for a Scholar-in-Training Award should submit their AACR membership applications by **November 12, 2020**. The AACR Membership Application Form is available on the AACR website at AACR.org/Membership. To apply for a Scholar-in-Training Award, an applicant must first submit an abstract, and then complete a separate award application. For details of the application process and the selection criteria, please visit AACR.org/SITA. Application deadline: **November 19, 2020**.

AACR GLOBAL SCHOLAR-IN-TRAINING AWARDS

Global Scholar-in-Training Awards (GSITA) are available for eligible early-career investigators in countries building cancer research capacities. Applicants must submit an abstract to the AACR Annual Meeting 2021 and then complete a separate GSITA application. Applicants must be members of the AACR in good standing (membership current through 2020). Nonmembers who wish to apply should submit a Membership Application Form by **November 12, 2020** before submitting their GSITA application. For additional details and a list of eligible developing countries, visit AACR.org/GSITA. Application deadline: **November 19, 2020**.

AACR-MINORITIES IN CANCER RESEARCH (MICR)-SPONSORED AWARDS

Minorities in Cancer Research (MICR)—a membership group within the AACR—is working to increase the number, participation, visibility, and recognition of minority scientists in cancer research. The AACR Minority and Minority-Serving Institution Faculty Scholar Awards and Minority Scholar Awards are two of several programs sponsored by MICR in support of its mission. These awards are generously supported by the NCI Center to Reduce Cancer Health Disparities. To learn more, please visit AACR.org/MICR or send an email to micr@aacr.org.

**AACR Minority and Minority-Serving Institution (MMSI) Faculty Scholar in Cancer Research Awards:**

Full-time minority faculty and faculty of Minority-Serving Institutions (Historically Black Colleges and Universities [HBCUs], Hispanic-Serving Institutions [HSIs], American Indian Tribally-Controlled Colleges and Universities [AITCCUs], and other postsecondary institutions as defined by the U.S. Department of Education) who present a proffered paper at this conference are encouraged to apply for this meritorious scholar award for travel. Supported by a generous grant from the Center to Reduce Cancer Health Disparities of the NCI, the purposes of these awards are to increase the scientific knowledge base of minority faculty and faculty at MSIs, to encourage
them in their research, and to assist in inspiring their students to pursue careers in cancer research. Only citizens of the United States or Canada or scientists who are permanent residents of these countries may receive one of these awards. For details or to submit an application, visit AACR.org/MSI. Application deadline: November 19, 2020.

AACR Minority Scholar in Cancer Research Awards: Presenters of a proffered paper who are full-time predoctoral (graduate or medical) students, residents, and clinical or postdoctoral fellows who are engaged in cancer research or have the training and potential to make contributions to this field are encouraged to apply for this meritorious scholar award for travel. Supported by a generous grant from the Center to Reduce Cancer Health Disparities of the NCI, this program applies only to racial/ethnic minority groups that have been identified by the NCI as being traditionally underrepresented in cancer and biomedical research, e.g., African American/Black, Alaskan Native, Hispanic/Latino, Native American, and Native Pacific Islander. Only citizens of the United States or Canada or scientists who are permanent residents of these countries may receive one of these awards. For details or to submit an application, visit AACR.org/MSA. Application deadline: November 19, 2020.

AACR-WOMEN IN CANCER RESEARCH (WICR) SCHOLAR AWARDS

The AACR-Women in Cancer Research (WICR) Scholar Award is a highly competitive award recognizing WICR members who are scientists-in-training and presenters of meritorious scientific papers at the AACR Annual Meeting. The purpose of this award is to increase the scientific knowledge base of WICR members and to encourage them to pursue careers in cancer research. All graduate students, medical students, residents, clinical fellows, and postdoctoral fellows are welcome to apply. For details or to apply, visit AACR.org/WSA. Application deadline: November 19, 2020.
**AACR Abstract Submission System.** Authors must submit abstracts for presentation at the Annual Meeting 2021 using the AACR Abstract Submission System, which is available at AACR.org/AACR2021. You can create, modify, and submit abstracts until the November 19, 2020, abstract deadline. Complete instructions on the use of the AACR Abstract Submission System will be provided on the website.

**Note for 2021:** Submit your abstract detailing how you use AACR Project GENIE data by the November 19, 2020, deadline for an opportunity to be featured in a special session during the Annual Meeting 2021. Simply include GENIE as a keyword during the submission process.

The Abstract Submission System has been optimized for the current versions of most browsers:
- **Google Chrome:** Version 23.0 or higher
- **Internet Explorer:** Version 9.0 or higher
- **Mozilla Firefox:** Version 27.0 or higher
- **Safari:** Version 7.1 or higher
- **Microsoft Edge:** Version 79.0 or higher

Browsers should be set to enable JavaScript and to accept cookies. Users who need assistance in properly updating and configuring their browsers should contact Abstract Submission Customer Service at 217-398-1792 or aacr@support.ctimeetingtech.com.

**Responsibilities of Authors.** By submitting an abstract for presentation at the AACR Annual Meeting, abstract authors agree and/or attest to the following:

- **Support for Abstract/Verification of Authorship.** All authors accept individual responsibility for the accuracy and integrity of statements in their abstract, and the submitting author is required to ensure that all authors have confirmed that all statements are an accurate reflection of the presented data and have agreed to the submission of the abstract and to their being listed as contributors prior to submission. Authors will be notified of their inclusion on an abstract via email.

- **Sponsorship of Abstracts.** The submitting author must provide the name of an AACR member who has agreed to sponsor the abstract, and the submitting author must attest that the permission of the member sponsor has been secured prior to initiating an abstract submission. See page 18 for Abstract Sponsorship Regulations.

- **Transfer of Copyright.** On behalf of all authors, the submitting author must assign and transfer copyright for the abstract to the AACR.

- **Presentation of Abstracts.** The submitting author for each abstract must designate a presenter who agrees to register for the meeting and participate in the corresponding session to discuss in detail the research presented in the published abstract. If the assigned presenter cannot participate in the meeting, the authors are expected to designate a replacement. If no presenter is available, or if the presenter does not register for the meeting, the abstract will be withdrawn.

- **Confirmation of No Prior Publication/Presentation.** Authors who submit an abstract confirm that they have not previously published these data, that they have not previously presented them at a large national annual scientific meeting, and that they are not planning to present or publish them prior to the dates of the AACR Annual Meeting 2021.

Exception: Encore presentations are permitted for clinical trials abstracts that are submitted for the January 11, 2021, clinical trials deadline. During the submission process, authors of encore clinical trials abstracts must provide the date and name of the meeting at which the original trial abstract was presented.

**Content of Abstracts.** Each abstract should contain (a) an introductory sentence indicating the purposes of the study; (b) a brief description of pertinent experimental procedures; (c) a summary of the new, unpublished data; and (d) a statement of the conclusions.

Abstracts should be carefully proofread to avoid errors in the published literature. American spelling should be used throughout; for more information regarding American spelling, please refer to *Scientific Style and Format: The CSE Manual for Authors, Editors, and Publishers, Eighth Edition* (Council of Science Editors, 2014).

**Abstract Control Number.** An Abstract Control Number (e.g., 21-A-1234-AACR) will be assigned to each abstract submitted online and will be listed on all email correspondence regarding the abstract. Please refer to the Abstract Control Number in any abstract communications.

**Financial Relationships of Coauthors.** Per ACCME regulations, the AACR must collect information on the financial relationships of all meeting presenters and abstract authors. You will be asked to disclose your financial relationships and the financial relationships...
of each of your coauthors. For more information on financial relationships, visit AACR.org/CME.

**Sponsor Permission and Information.** Each abstract must be sponsored by an AACR member. You must secure the permission of the sponsor before submitting the abstract. For details, see the “Abstract Sponsorship Regulations” on page 18.

**Length of Abstracts.** The combined length of the abstract body, title, and tables may not exceed 2,600 characters, not including spaces and the author string. Tables count for 800 characters against the limit. Submission cannot be completed for abstracts that exceed this limit.

**Abstract Category, Subcategory, and Subclassification.** You must select a category, subcategory, and subclassification for your abstract. See pages 19–23 for details.

**Disclosure of Chemical Structures.** At the time of abstract submission, the submitting author is required to state whether chemical compounds were used in the scientific work to generate the data in the proffered paper. Chemical compounds are defined as low-molecular-weight (generally <1000 g/mol) organic or inorganic molecules, peptides, or proteins/nucleic acids cocrystallized with low-molecular-weight molecules. If chemical compounds were used, the corresponding author is further required to indicate whether the complete chemical structures of the compounds used will be disclosed at the time of presentation at the meeting. The chemical structures are not required to be included at the time of abstract submission; rather, an indication of the intent to disclose any such structures at the time of presentation is required.

The Program Committee will then evaluate the information provided by the corresponding author and determine the acceptability of the proffered paper for presentation. Those who do not intend to disclose chemical structures may have their abstracts rejected for participation; however, a limited number of these abstracts without chemical structures may be accepted for presentation if deemed to be of sufficient scientific merit.

**Submission Fee.** Each abstract submitted must be accompanied by a $65 abstract submission fee. The submission fee can be paid by credit card or check. The fee is nonrefundable regardless of the final disposition of the abstract.

**Abstract Deadline.** The deadline for abstract submissions is 11:59 p.m. U.S. ET, Thursday, November 19, 2020. Abstracts submitted after the deadline will not be considered by the Program Committee. No significant changes may be made to abstracts after the November 19, 2020, deadline.

**Note:** Submitting an abstract for presentation at the AACR Annual Meeting 2021 does not constitute registration for the meeting. Abstract presenters must register to attend the meeting at AACR.org/AACR2021.

**Late-Breaking Abstract Deadline.** The deadline for late-breaking abstracts is 11:59 p.m. U.S. ET, Monday, January 11, 2021. Abstracts detailing highly significant and timely findings in any area of cancer research that were not available at the time of the regular abstract deadline will be considered for presentation at the Annual Meeting. Only those abstracts that are deemed to be of high scientific priority will be accepted.

Abstract submission fees and sponsorship regulations also apply to late-breaking abstracts.

**Clinical Trials Abstract Deadline.** All abstracts describing clinical trials (including placeholder abstracts) should be submitted as late-breaking abstracts. The deadline for clinical trials abstracts is 11:59 p.m. U.S. ET, Monday, January 11, 2021. Final data for placeholder abstracts are due Thursday, February 4, 2021 (see page 9). Abstract submission fees and sponsorship regulations also apply to clinical trials abstracts.

**Publication Opportunity.** For consideration of simultaneous publication in an AACR journal, please contact the AACR Publishing Division at pubs@aacr.org.

**Presentation of Proffered Papers at the AACR Annual Meeting.** Every proffered abstract that has been accepted for publication in the online Proceedings must have a corresponding presentation at the meeting. Specifically, the author listed as the presenter for an accepted proffered paper must participate in the corresponding session to discuss in detail the research outlined in the published abstract, according to the specific guidelines of the session. Presentation formats for 2021 include ePosters with enhanced engagement and networking opportunities and short talks in minisymposia. If, due to unforeseen circumstances, the designated presenter is unavailable to register for the meeting and participate in the session to present the paper, he or she must contact the AACR Program Development Department to designate a coauthor to serve as the presenter. If no abstract authors are available to register for the meeting and present the data, the presenter must withdraw the abstract immediately by contacting the AACR Program Development Department at 215-440-9300 or abstractchanges@aacr.org. Failure to comply with these regulations pertaining to abstract presentation may result in actions including, but not limited to:
The withdrawal of the abstract from the session
The removal of the abstract from the online Proceedings
The loss of future sponsorship privileges for the sponsor of the abstract
The loss of future abstract submission/authorship privileges for the presenter of the abstract

Deadline for Withdrawal of Abstracts. Requests to withdraw regular abstracts will be accepted through Monday, February 22, 2021. Requests to withdraw late-breaking or clinical trials abstracts will be accepted through Tuesday, March 9, 2021. Withdrawal requests must be sent by email to abstractchanges@aacr.org. Withdrawal requests must include the Abstract Control Number and title as well as an explanation of the reason for withdrawal.

ABSTRACT SPONSORSHIP REGULATIONS

Expanded Abstract Sponsorship Privileges for AACR Members

Expanded abstract sponsorship privileges for selected AACR member types are available for the AACR Annual Meeting 2021, as outlined below:

★ Active, Honorary, and Emeritus Members may now sponsor an unlimited number of abstracts for presentation at the meeting. (As always, members must verify the content, authenticity, and quality of the abstracts they agree to sponsor.)

★ Affiliate Members are still permitted to sponsor one abstract for each submission deadline provided that they are the presenter of the abstract. However, Affiliate Members are no longer required to provide an endorser for their abstract.

Members must be in good standing in order to sponsor and endorse abstracts for presentation (see below for details). To be in good standing for the November 19 regular abstract deadline, member dues must be paid in full through 2020. To be in good standing for the January 11 late-breaking and clinical trials abstract deadline, member dues must be paid in full through 2021. Associate, Honorary, and Emeritus Members are exempt from the payment of dues; therefore, this regulation does not apply to them.

1. Each abstract submitted for presentation at the AACR Annual Meeting must be sponsored by an Active, Emeritus, Honorary, Affiliate, or Associate AACR Member in good standing. (Student members are not eligible to sponsor an abstract.)

2. An Active, Emeritus, or Honorary Member may sponsor an unlimited number of abstracts and may use his or her sponsorship privileges in two ways: (a) to sponsor abstracts on which he or she is listed as an author, or (b) to sponsor abstracts submitted by colleagues on which he or she is not listed as an author.

3. An Associate Member in good standing may sponsor one abstract for each submission deadline provided that (a) he or she is the presenter of the abstract, and (b) an Active, Emeritus, or Honorary Member in good standing endorses the work. Active, Emeritus, and Honorary Members may endorse an unlimited number of abstracts while still retaining their right to sponsor an unlimited number of abstracts.

4. An Affiliate Member in good standing may sponsor one abstract for each submission deadline provided that he or she is the presenter of the abstract. (Affiliate Members are no longer required to provide an endorser.)

5. Permission to list an AACR member as a sponsor or endorser must be obtained prior to selecting the sponsor/endorser in the Online Abstract Submission System. Individuals listed as sponsors or endorsers of abstracts will receive a notification of sponsorship or endorsement via email.

6. The sponsor must verify the content, authenticity, and quality of the abstract. Sponsorship of an abstract implies support for the data and the interpretations contained therein.

COMPLIANCE WITH THESE REGULATIONS IS THE RESPONSIBILITY OF THE AUTHORS. Adherence to these rules will be strictly enforced. Violations will result in the rejection of the abstract by the Program Committee.

MEMBERSHIP APPLICATION DEADLINES FOR ABSTRACT SPONSORSHIP

Nonmember individuals interested in joining the AACR and sponsoring an abstract for Annual Meeting 2021 must submit an application for membership no later than November 12, 2020. Individuals interested in joining the AACR and sponsoring a clinical trial or late-breaking abstract must submit an application for membership no later than January 7, 2021. Membership questions may be directed to membership@aacr.org.
The 2021 abstract categories, along with their related subcategories and subclassifications, are listed below. When you use the Abstract Submission System, these options will be available for your selection. Please choose the appropriate category, subcategory, and subclassification that best describe the scientific content of the abstract and the particular scientific audience you wish to reach. This information will be utilized by the members of the Program Committee in their review of abstracts and planning of sessions at the Annual Meeting 2021. Please note that these abstract categories may or may not be used as Annual Meeting session titles. Before making your selection, please scan the entire list for the most appropriate abstract category, subcategory, and subclassification. The regular abstract submission deadline is Thursday, November 19, 2020 (11:59 p.m. ET) and the late-breaking and clinical trials abstract submission deadline is Monday, January 11, 2021 (11:59 p.m. ET).

The AACR is committed to raising awareness about the enormous public health challenge of cancer health disparities and racial inequities. We encourage you to view the relevant abstract subcategories and subclassifications in the listing below. Also, a new submission category, COVID-19 and Cancer, provides an opportunity to submit novel work in this timely and critically important area.

**MCB** Molecular and Cellular Biology, Genetics

**MCB01** Cell Growth Signaling Pathways
- Cell signaling
- Cell-cell interactions
- Growth factors
- GTPases, their regulators, and effectors
- Receptors
- Tumor-stromal cell interactions
- Ubiquitin and ubiquitin-like proteins
- Other

**MCB02** Cell Death
- Apoptosis
- Autophagy
- Bcl-2 family proteins
- Caspases
- Effectors of apoptosis
- Inhibitor of apoptosis (IAP) family proteins
- Necrosis and necroptosis
- Transcriptional control of apoptosis
- Other

**MCB03** Oncogenes and Tumor Suppressor Genes
- Cytoplasmic signal transducers
- Genotype/phenotype correlations
- Nuclear oncoproteins and tumor suppressor genes
- Oncogene growth factors and their receptors
- Tumor suppressor genes
- Other

**MCB04** Gene Regulation and Transcription Factors
- Chromatin structure and function
- Gene expression
- Mechanisms of transcription
- Oncogenic transcription factors
- Posttranscriptional and translational control
- Promoters and enhancers of transcription
- Protein-protein interactions in transcription factor function

**MCB05** Epigenetics
- Chromatin structure and function
- DNA methylation
- Epigenetic changes as molecular markers of cancer
- Epigenomics
- Gene silencing
- Histone modification
- Other

**MCB06** Cell Cycle
- CDKs and CDK inhibitors
- Cell cycle checkpoints
- Control of cell cycle progression
- Mitosis
- Telomeres and telomerase
- Other

**MCB07** DNA Damage and Repair
- Chromosomal structural alterations/translocations
- Genomic instability
- Homologous recombination
- Mechanisms of genomic alterations
- Radiation-induced DNA damage
- Other

**MCB08** Metabolism and Cancer
- Metabolic pathways
- Metabolomics
- Mitochondrial function
- Signaling pathways that regulate metabolism
- Warburg effect
- Other

**MCB09** Genomics
- (See also BSB01: Bioinformatics and Computational Biology)
- Functional genomics
- Genomic profiling of tumors
- High-throughput sequencing
- Large-scale approaches to cancer gene discovery
- Microarrays
- Other

**MCB10** microRNAs and Other Noncoding RNAs
- Epigenetic control of miRNA expression
- miRNA profiling in cancer
- miRNA regulation of cancer biology
- miRNA-based diagnostics
- miRNA-based therapeutics
- miRNAs as tumor suppressors/oncogenes
- Noncoding RNAs
- Other

**MCB11** Cellular Stress Responses
- Hypoxia
- Oxidative stress
- Senescence
- Unfolded protein response
- Other

**BSB** Bioinformatics, Convergence Science, and Systems Biology

**BSB01** Bioinformatics and Computational Biology
- (See also MCB09: Genomics)
- Analytic pipeline optimization
- Application of bioinformatics to cancer biology
- Database resources
- Molecular modeling
- New algorithms
- New software for data analysis
- Sequence analysis
- Statistical methods
- Other
<table>
<thead>
<tr>
<th>Category</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>TB</strong></td>
<td>Tumor Biology</td>
</tr>
<tr>
<td><strong>TB01</strong></td>
<td>Nonclinical Models of Cancer</td>
</tr>
<tr>
<td>3-D and tissue recombinant models</td>
<td></td>
</tr>
<tr>
<td>Developmental phenotypes of cancer genes</td>
<td></td>
</tr>
<tr>
<td>Human-in-mouse models of human cancer</td>
<td></td>
</tr>
<tr>
<td>Model organisms in drug discovery</td>
<td></td>
</tr>
<tr>
<td>Mouse models of human cancer</td>
<td></td>
</tr>
<tr>
<td>Noninvasive imaging in animal models</td>
<td></td>
</tr>
<tr>
<td>Organoids</td>
<td></td>
</tr>
<tr>
<td>Patient-derived xenograft models</td>
<td></td>
</tr>
<tr>
<td>Zebrafish models of cancer</td>
<td></td>
</tr>
<tr>
<td>Other animal and cell models of cancer</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td></td>
</tr>
<tr>
<td><strong>TB02</strong></td>
<td>Stem Cell Biology</td>
</tr>
<tr>
<td>Adult stem cells</td>
<td></td>
</tr>
<tr>
<td>Cancer stem cells</td>
<td></td>
</tr>
<tr>
<td>Developmental pathways in cancer</td>
<td></td>
</tr>
<tr>
<td>Embryonic stem cells</td>
<td></td>
</tr>
<tr>
<td>Stem cell markers</td>
<td></td>
</tr>
<tr>
<td>Stem cells and regenerative medicine in oncology</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td></td>
</tr>
<tr>
<td><strong>TB03</strong></td>
<td>Tumor Adhesion</td>
</tr>
<tr>
<td>Cell adhesion and extracellular matrix</td>
<td></td>
</tr>
<tr>
<td>Cell-cell adhesion</td>
<td></td>
</tr>
<tr>
<td>Drug resistance</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td></td>
</tr>
<tr>
<td><strong>TB04</strong></td>
<td>Invasion and Metastasis</td>
</tr>
<tr>
<td>Actin cytoskeleton</td>
<td></td>
</tr>
<tr>
<td>Biomarkers of metastasis</td>
<td></td>
</tr>
<tr>
<td>Epithelial/mesenchymal transition (EMT and MET)</td>
<td></td>
</tr>
<tr>
<td>Expression profiling of tumor progression and metastasis</td>
<td></td>
</tr>
<tr>
<td>Genes that regulate migration and invasion</td>
<td></td>
</tr>
<tr>
<td>Imaging of tumor progression and metastasis</td>
<td></td>
</tr>
<tr>
<td>Invasion and migration</td>
<td></td>
</tr>
<tr>
<td>Metastasis suppressor genes</td>
<td></td>
</tr>
<tr>
<td>Metastasis-promoting genes</td>
<td></td>
</tr>
<tr>
<td>Premetastatic niche</td>
<td></td>
</tr>
<tr>
<td>Therapeutic metastasis prevention</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td></td>
</tr>
<tr>
<td><strong>TB05</strong></td>
<td>Angiogenesis</td>
</tr>
<tr>
<td>Angiogenesis and angiogenesis inhibitors</td>
<td></td>
</tr>
<tr>
<td>Host-tumor interactions</td>
<td></td>
</tr>
<tr>
<td>Molecular mechanisms of angiogenesis</td>
<td></td>
</tr>
<tr>
<td>Novel pro- and antiangiogenic factors</td>
<td></td>
</tr>
<tr>
<td>Tumor microcirculation and the microenvironment</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td></td>
</tr>
<tr>
<td><strong>TB06</strong></td>
<td>Tumor Microenvironment</td>
</tr>
<tr>
<td>Chemokines in the microenvironment</td>
<td></td>
</tr>
<tr>
<td>Drug targets in the microenvironment</td>
<td></td>
</tr>
<tr>
<td>Extracellular matrix and integrins</td>
<td></td>
</tr>
<tr>
<td>Gene expression in the microenvironment</td>
<td></td>
</tr>
<tr>
<td>Immune cells in the tumor microenvironment</td>
<td></td>
</tr>
<tr>
<td>Immunity and the microenvironment</td>
<td></td>
</tr>
<tr>
<td>Inflammatory cells as regulators of tumor growth</td>
<td></td>
</tr>
<tr>
<td>Microbiome</td>
<td></td>
</tr>
<tr>
<td>Organ-specific microenvironments</td>
<td></td>
</tr>
<tr>
<td>Proteases and inhibitors in the microenvironment</td>
<td></td>
</tr>
<tr>
<td>Tumor dormancy</td>
<td></td>
</tr>
<tr>
<td>Tumor/stromal interactions</td>
<td></td>
</tr>
<tr>
<td>Tumor-immune system interactions</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td></td>
</tr>
<tr>
<td><strong>TB07</strong></td>
<td>In Vivo Imaging</td>
</tr>
<tr>
<td>(See also CL01: Translational Research – Molecular Biology in the Clinic)</td>
<td></td>
</tr>
<tr>
<td>Advanced nanotechnology and imaging</td>
<td></td>
</tr>
<tr>
<td>Application of imaging technology to the clinic</td>
<td></td>
</tr>
<tr>
<td>Imaging in animal models</td>
<td></td>
</tr>
<tr>
<td>Imaging of molecular and cellular events in the tumor microenvironment</td>
<td></td>
</tr>
<tr>
<td>Imaging of molecular and cellular events in tumors and tumor cells</td>
<td></td>
</tr>
<tr>
<td>Imaging the immune response</td>
<td></td>
</tr>
<tr>
<td>Imaging tumor metabolism</td>
<td></td>
</tr>
<tr>
<td>New targets for imaging</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td></td>
</tr>
<tr>
<td><strong>TB08</strong></td>
<td>Pediatric Cancer - Basic Science</td>
</tr>
<tr>
<td>(See also CL02: Pediatric Cancer - Clinical Investigations; CT04: Phase I, II, or III Clinical Trials in Pediatric Cancer)</td>
<td></td>
</tr>
<tr>
<td>Developmental origins and drivers of pediatric cancer</td>
<td></td>
</tr>
<tr>
<td>Pediatric cancer epigenomics and genomics</td>
<td></td>
</tr>
<tr>
<td>Pediatric cancer models</td>
<td></td>
</tr>
<tr>
<td>Pediatric cancer tumor microenvironment and tumor heterogeneity</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td></td>
</tr>
<tr>
<td><strong>TB09</strong></td>
<td>Radiation Science</td>
</tr>
<tr>
<td>(See also CL07: Radiation Oncology; ET09: Preclinical Radiotherapeutics)</td>
<td></td>
</tr>
<tr>
<td>Modulators of radiation response</td>
<td></td>
</tr>
<tr>
<td>Photobiology/photodynamic therapy</td>
<td></td>
</tr>
<tr>
<td>Radiation dose fractionation</td>
<td></td>
</tr>
<tr>
<td>Radiation-activated signaling pathways</td>
<td></td>
</tr>
<tr>
<td>Radiation-induced gene expression</td>
<td></td>
</tr>
<tr>
<td>Radiation-induced resistance</td>
<td></td>
</tr>
<tr>
<td>Radiobiology research</td>
<td></td>
</tr>
<tr>
<td>Radioprotectors and radiosensitizers</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td></td>
</tr>
<tr>
<td><strong>TB10</strong></td>
<td>Tumor Evolution and Heterogeneity</td>
</tr>
<tr>
<td>Causes and consequences of tumor heterogeneity</td>
<td></td>
</tr>
<tr>
<td>Complex adaptive systems</td>
<td></td>
</tr>
<tr>
<td>Methods to measure tumor evolution and heterogeneity</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td></td>
</tr>
<tr>
<td><strong>TB11</strong></td>
<td>Carcinogenesis</td>
</tr>
<tr>
<td>Carcinogenesis: Chemical, environmental, and molecular</td>
<td></td>
</tr>
<tr>
<td>Mutagenesis</td>
<td></td>
</tr>
<tr>
<td>Tumor initiation and promotion</td>
<td></td>
</tr>
<tr>
<td>Viral-induced carcinogenesis</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td></td>
</tr>
<tr>
<td><strong>CH</strong></td>
<td>Cancer Chemistry</td>
</tr>
<tr>
<td><strong>CH01</strong></td>
<td>Drug Discovery, Design, and Delivery</td>
</tr>
<tr>
<td>Basic and applied nanotechnology and therapeutics</td>
<td></td>
</tr>
<tr>
<td>Chemoinformatics, in silico screening, and computational methods</td>
<td></td>
</tr>
<tr>
<td>Drug delivery</td>
<td></td>
</tr>
<tr>
<td>Drug design</td>
<td></td>
</tr>
<tr>
<td>High-throughput screening (assays and libraries)</td>
<td></td>
</tr>
<tr>
<td>Lead identification</td>
<td></td>
</tr>
<tr>
<td>Lead optimization</td>
<td></td>
</tr>
<tr>
<td>Nanotechnology drug delivery</td>
<td></td>
</tr>
<tr>
<td>Natural products</td>
<td></td>
</tr>
<tr>
<td>Synthesis, metabolism, and disposition</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td></td>
</tr>
<tr>
<td><strong>CH02</strong></td>
<td>Structural and Chemical Biology</td>
</tr>
<tr>
<td>Chemical genetics and genomics</td>
<td></td>
</tr>
<tr>
<td>Nanotechnology in chemical biology</td>
<td></td>
</tr>
<tr>
<td>Small molecule, protein, and nucleic acid interactions</td>
<td></td>
</tr>
<tr>
<td>Target identification, small molecule probes, and libraries</td>
<td></td>
</tr>
<tr>
<td>X-ray and NMR structures</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td></td>
</tr>
<tr>
<td><strong>CH03</strong></td>
<td>Proteomics and Mass Spectrometry</td>
</tr>
<tr>
<td>Biological mass spectrometry and systems biology</td>
<td></td>
</tr>
<tr>
<td>Proteomics and biomarker discovery</td>
<td></td>
</tr>
<tr>
<td>Proteomics and signaling networks</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td></td>
</tr>
</tbody>
</table>
ET  Experimental and Molecular Therapeutics

ET01  Drug Discovery
Antibody technologies
Biochemical modulators of the therapeutic index
Combination chemotherapies
Differentiation therapy
New targets
Novel assay technology
Novel drug delivery systems
Targeting the tumor microenvironment in drug development
Other

ET02  Mechanisms of Drug Action
Cell cycle mechanisms of anticancer drug action
Cellular responses to anticancer drugs
Interactions of new agents with radiation
Role of the microenvironment in therapeutic response
Other

ET03  Drug Resistance
Drug resistance in molecular targeted therapies
Drug transport and metabolism
Novel mechanisms
Regulation of gene expression in drug resistance
Reversal of drug resistance
Other

ET04  Molecular Targets
Cell death pathways and treatment
Identification of molecular targets
Modulation of DNA repair
Molecular classification of tumors for diagnostics, prognostics, and therapeutic outcomes
New nonclinical models for targets
Other

ET05  Pharmacology, Pharmacogenetics, and Pharmacogenomics
Cellular pharmacology
Molecular pharmacology
Pharmacogenetics and therapeutic response
Pharmacogenomics
Pharmacokinetics and pharmacodynamics
Preclinical toxicology
Other

ET06  Small Molecule Therapeutic Agents
DNA-reactive agents
Epigenetic targets
HDAC and methyltransferase inhibitors
Novel antitumor agents
Novel targets and pathways
PI3K/AKT inhibitors
Proteasome inhibitors
Topoisomerases
Tubulin agents
Tyrosine kinase and phosphatase inhibitors
Other

ET07  Biological Therapeutic Agents
Antireceptors
Apoptosis: Therapeutic manipulation
Growth factor receptors and other surface antigens as targets for therapy
Oncogenes, tumor suppressor genes, and gene products as targets for therapy
Protein kinases and phosphatases as targets for therapy
Role of microenvironment in therapeutic response
Other

ET08  Gene and Vector-Based Therapy
Antisense molecules
Gene therapy and radiation studies
Immune modulators
Vector systems and targeting strategies
Other

ET09  Preclinical Radiotherapeutics
Modification of radiosensitivity
Molecular targets of radiation response
Normal tissue/cellular stress responses to radiation
Radioprotectors and radiosensitizers
Radiotherapeutic combinations
Other

IM  Immunology

IM01  Tumor Immunobiology
Adaptive immunity in tumors
Epigenetic regulation of tumor immunity
Inflammation and cancer: Metastasis
Inflammation and cancer: Tumor initiation and progression
Innate immunity to tumors
Microbiome, inflammation, and cancer
Novel animal models
Oncogenic pathway-mediated regulation of inflammation and tumor immunity
Tumor antigenicity/processing and presentation
Tumor-induced immune suppression: Extrinsic factors
Tumor-induced immune suppression: Intrinsic factors
Other

IM02  Immunotherapy, Preclinical and Clinical
Adoptive cell therapy
Combination immunotherapies
Immune checkpoints
Immune mechanisms invoked by other therapies including chemotherapy
Immune mechanisms invoked by radiation therapy
Immune monitoring/clinical correlates
Immune response to therapies
Immunomodulatory agents and interventions
Inflammation, immunity, and cancer
Modifiers of the tumor microenvironment
Therapeutic antibodies, including engineered antibodies
Vaccines (oncolytic and prophylactic)
Other

CT  Clinical Trials
(Including Combination and Immunotherapy Trials)
All clinical trials should be submitted by the January 11, 2021 clinical trials abstract deadline.

CT01  Phase I Adult Clinical Trials
CT02  Phase II Adult Clinical Trials
CT03  Phase III Adult Clinical Trials

CT04  Phase I, II, or III Clinical Trials in Pediatric Cancer
CT05  Phase I, II, or III Clinical Trials in the Elderly
CT06  Phase I, II, or III Clinical Trials in Minorities and Medically Underserved Populations
## Abstract Categories (cont'd)

### CL01  Clinical Research – Molecular Biology in the Clinic
(See also: TB07: In Vivo Imaging)

- Clinical imaging
- Cytogenetics and clinical molecular genetics
- Epigenetic therapy
- Functional and molecular imaging
- Laboratory correlates for targeted agents
- Molecular classification of tumors
- Radiomics
- Tumor staging: Correlation of clinical and molecular markers

### CL02  Pediatric Cancer – Clinical Investigations
(See also CT04: Phase I, II, or III Clinical Trials in Pediatric Cancer; TB08: Pediatric Cancer – Basic Science)

- Adolescent and young adult oncology
- Childhood cancer drug development
- Immunotherapeutic approaches to pediatric cancer
- Pediatric cancer predisposition and surveillance
- Survivorship, late effects, and secondary cancers
- Therapeutic dosing, resistance, and combination therapy approaches in pediatric oncology
- Translational pediatric cancer research

### CL03  Clinical Research in the Elderly

- Aging, immunity, and cancer

### CL04  Clinical Research in Racial and Ethnic Minorities and Other Underserved Populations

- Biobanking/biospecimen collection
- Clinical trial design
- Community engaged research/community-based participatory research
- Patient accrual and retention
- Patient navigation

### CL05  Biostatistics in Clinical Trials

- Design and analysis of clinical trials
- New study designs: Theory, methodology, and modeling
- Statistical modeling for cancer studies

### CL06  Immuno-oncology
(See also ET07: Biological Therapeutic Agents; IM02: Immunotherapy, Preclinical and Clinical)

- Adoptive cell therapy
- Combination immunotherapies
- Immune checkpoints
- Immune mechanisms invoked by other therapies including chemotherapy
- Immune mechanisms invoked by radiation therapy
- Immune monitoring/clinical correlates
- Immune response to therapies
- Immunomodulatory agents and interventions
- Inflammation, immunity, and cancer
- Modifiers of the tumor microenvironment
- Therapeutic antibodies, including engineered antibodies
- Vaccines (oncolytic and prophylactic)

### CL07  Radiation Oncology
(See also TB09: Radiation Science; ET09: Preclinical Radiotherapeutics)

- Clinical radiotherapeutic studies
- Interventional radiology
- Modification of radiosensitivity
- Radiation-immunotherapy and other radiotherapeutic combinations
- Radiation-induced late effects/secondary cancers
- Radiation-induced resistance

### CL08  Surgical Oncology (including Prophylactic Surgery)

- Surgical oncology

### CL09  Clinical Endocrinology
(See also EN01: Molecular, Preclinical, and Clinical Endocrinology)

- Endocrine-related cancers
- Hormone receptors and diagnosis/prognosis
- Hormone signaling and inhibitors
- Hormone synthesis, metabolism, and inhibitors
- Neuroendocrine and other endocrine factors
- Nuclear receptors: Structure and function
- Preclinical studies of endocrine-related cancers
- Receptors and signal transduction
- Steroid hormone receptors

### CL10  Survivorship Research and Supportive Care

- Biology of cell and tissue damage
- Comparative effectiveness research and cost-effective studies
- Late effects and second cancers
- Psycho-oncology
- Supportive care, palliation, and pain management
- Translational survivorship research

### CL11  Biomarkers

- Biomarkers predictive of therapeutic benefit
- Diagnostic biomarkers
- Early detection biomarkers
- Liquid biopsies: Circulating DNA
- Liquid biopsies: Circulating tumor cells
- Metastasis biomarkers
- Prognostic biomarkers

### CL12  Clinical Outcomes Research

- Clinical outcomes research

### EN  Endocrinology

#### EN01  Molecular, Preclinical, and Clinical Endocrinology
(See also CL09: Clinical Endocrinology)

- Endocrine-related cancers
- Growth factors, receptors, and signal transduction
- Hormone receptors and diagnosis/prognosis
- Hormone signaling and inhibitors
- Hormone synthesis, metabolism, and inhibitors
- Neuroendocrine and other endocrine factors
- Nuclear receptors: Structure and function
- Preclinical studies of endocrine-related cancers
- Receptors and signal transduction
- Steroid hormone receptors
EP Epidemiology (including Genetic, Molecular, and Integrative Epidemiology)

EP01 Epidemiology
- Biomarkers of endogenous or exogenous exposures, early detection, and biologic effects
- Biomarkers of prognosis
- Cancer health disparities research
- Descriptive epidemiology, covering cancer incidence, mortality, clusters, and trends
- Diet, alcohol, tobacco use, and other lifestyle risk factors
- Environmental and occupational risk factors
- Familial and hereditary cancers
- Functional studies of genetic variants
- Gene-gene and gene-environment interactions
- Genome-wide association studies (GWAS)/post-GWAS
- Health services and comparative effectiveness research
- Infection and immune factors
- Next-generation sequencing in epidemiology studies (whole genome, exome, targeted, or fine-mapping)
- Pathway and candidate gene studies of risk or prognosis
- Pharmacoprevalence
- Preneoplastic and tumor markers
- Primary and secondary intervention studies
- Risk prediction models for incidence, prognosis, and/or mortality
- Screening and early detection
- Statistical and epidemiological methodology
- Surveillorship research

PR Prevention, Early Detection, and Interception

PR01 Preclinical Prevention, Early Detection, and Interception
- Animal models in prevention
- Biological and biochemical mechanisms in prevention
- Biomarkers and intervention studies
- Cellular models
- Chemoprevention studies
- Diet, nutrition, and cancer
- Microbiome and prevention
- Molecular markers in prevention research
- Molecular targets for prevention
- New agent development
- Screening and early detection

PR02 Clinical Prevention, Early Detection, and Interception
- Application of molecular pathology in clinical prevention
- Biomarkers and intervention studies
- Cancer health disparities research
- Cancer surveillance and screening studies
- Chemoprevention clinical trials
- Genetic markers as surrogate endpoints in prevention trials
- Genomics and proteomics in cancer risk and response assessment
- Infections and viral-related cancers
- Microbiome and prevention
- Prevention and treatment of premalignant lesions (intraepithelial neoplasia)
- Prevention of second cancers
- Recruitment of racial and ethnic minorities and other underserved populations in clinical prevention trials
- Screening and early detection

COVID COVID-19 and Cancer

COVID01 Intersection of the Biology of SARS-CoV-2 and Cancer
- Biomarkers/predictors of COVID-19 and cancer
- Host genomics and genetics
- Immunobiology
- Pathophysiology
- Viral evolution

COVID02 Diagnostics for COVID-19 Testing: Design, Development, and Validation

COVID03 Cancer Drug Repurposing to Treat COVID-19

COVID04 COVID-19 Vaccine Development

COVID05 Effects of Cancer Immunotherapies on Patients with COVID-19 (with or without Cancer)

COVID06 Clinical Trials
- [See also CT07: Clinical Trials for COVID-19 (Phase I–Phase IV and Trials in Progress)]
  - Phase I
  - Phase II
  - Phase III
  - Phase IV, observational, and expanded access
  - Clinical trials in progress

COVID07 Continuity of Cancer Care
- Long-term cancer outcomes
- Novel health care strategies (including telehealth and digital health)
- Palliative care
- Patient management
- Treatment modifications
- Other

COVID08 Effects of COVID-19 on Cancer Survivorship
- Long-term health-related quality of life issues
- Psychosocial impact on patients and health care workers
- Other

COVID09 Risk Factors and Comorbidities Resulting in Adverse Outcomes for Cancer Patients with COVID-19

COVID10 Cancer Prevention and Early Detection during the COVID-19 Pandemic

COVID11 Epidemiology and Registries of COVID-19 and Cancer (including Biorepositories)

COVID12 Health Inequities and Disparities during the COVID-19 Pandemic

COVID13 Science and Public Policy
- Effects of regional public health policies
- Funding
- Regulatory science and policy
- Workforce
- Other

RSP Regulatory Science and Policy

RSP01 Regulatory Science and Policy
- Biosimilars and generics
- Clinical trial design and accrual
- Combination therapies and codetermination of investigational agents and diagnostics
- Data science and informatics
- Novel endpoints and biomarkers
- Real-world evidence and retrospective analyses
- Tobacco and e-cigarette regulation
- Other

SHP Science and Health Policy

SHP01 Science and Health Policy
- Cancer health disparities
- Cancer survivorship
- Comparative effectiveness research
- Implementation science
- Patient advocacy and engagement
- Value and cost issues in cancer care
- Other
AACR MEMBERSHIP: THE ESSENTIAL ASSOCIATION FOR YOU

With over 47,000 members in 127 countries and territories around the world, the AACR is a dynamic and vibrant organization that offers its members opportunities to participate more fully in the global initiative to eliminate cancer. AACR membership is available to those who conduct cancer research and related biomedical science, both senior and early-career investigators, as well as to those health care professionals, research administrators, cancer survivors and advocates, students, and others who share the AACR’s vision and support our mission to accelerate the prevention and cure of all cancers.

AACR membership categories promote the professional growth of those in training, facilitate collaborations for established scientists, and provide support for all working in cancer research. Special rates are available to members located in countries with emerging economies as designated by the World Bank. For a complete list of countries with emerging economies, please visit AACR.org/International.

MEMBERSHIP APPLICATION DEADLINES FOR ABSTRACT SPONSORSHIP

Nonmember individuals interested in joining the AACR and sponsoring an abstract must submit an application for membership no later than November 12, 2020. Individuals interested in joining the AACR and sponsoring a late-breaking abstract must submit an application for membership no later than January 7, 2021.

ABSTRACT SPONSORSHIP

<table>
<thead>
<tr>
<th>Membership Application Deadlines</th>
<th>Abstract Application Deadlines</th>
</tr>
</thead>
<tbody>
<tr>
<td>November 12, 2020</td>
<td>November 19, 2020</td>
</tr>
<tr>
<td>January 7, 2021</td>
<td>January 11, 2021 (Late-Breaking and Clinical Trials)</td>
</tr>
</tbody>
</table>

SCHOLAR AWARDS

<table>
<thead>
<tr>
<th>Membership Application Deadline</th>
<th>All Travel Awards Application Deadline</th>
</tr>
</thead>
<tbody>
<tr>
<td>November 12, 2020</td>
<td>November 19, 2020</td>
</tr>
</tbody>
</table>

Contact the AACR Membership Department with any questions at 215-440-9300 or membership@aacr.org.

AACR MEMBERSHIP CATEGORIES

Active Membership is open to investigators worldwide who have established a record of scholarly activity resulting in original peer-reviewed articles in publications relevant to cancer research and biomedical science.

Affiliate Membership is open to qualified individuals who are health professionals working in support of cancer research and biomedical science; survivors and advocates who are members of organizations whose mission includes the advancement of cancer research; educators; or other professionals who are interested in and/or make substantial contributions to the cancer field.

Associate Membership is open to graduate students, medical students and residents, and clinical and postdoctoral fellows who are enrolled in education or training programs that could lead to careers in cancer research and the related sciences. Annual dues are not required.
Student Membership is open to persons who have manifested an interest in cancer and the related biomedical sciences and who are enrolled in a program leading to a high school diploma or a bachelor’s degree. Annual dues are not required.

Sustaining Membership is open to organizations in recognition of annual payment of dues and other substantial contributions in support of the mission, purposes, and activities of the Association. Annual dues are determined by the Sustaining Member level.

Emeritus Membership is open to existing Active Members who have reached the age of 70 years, who are disabled, or who are retired.

Honorary Membership is open to distinguished individuals who have made extraordinary contributions to the advancement of cancer research either through outstanding personal scientific activity or through exceptional leadership in cancer research. (Candidates for Honorary Membership are invited through a special selection process.)

Please contact the Membership Department at membership@aacr.org or 215-440-9300 and a membership representative will gladly assist with any questions. Not yet a member? Apply for membership at myAACR and join us in the global conquest of cancer.
OPPORTUNITIES TO SUPPORT THE AACR FOUNDATION

The AACR Foundation welcomes support from corporations, foundations, individuals, and other organizations that share its mission and are interested in helping to defray the costs of presenting this important international meeting on the latest developments in cancer research. For a complete list of support opportunities and their many benefits, please contact Peter VanPelt, Senior Director, Corporate and Foundation Relations, at 215-446-7256 or via email at peter.vanpelt@aacr.org.

FELLOWS OF THE AACR ACADEMY

The AACR Academy was established in 2013 to honor distinguished scientists whose major scientific contributions have propelled significant innovation and progress against cancer. Those elected, known as Fellows of the AACR Academy, constitute a global brain trust of individuals who are instrumental in advancing the mission of the AACR to prevent and cure all cancers through research, education, communication, and collaboration.

The AACR Academy is currently led by Dr. Judy E. Garber and a Steering Committee of ten additional Fellows who serve as a voice for all Fellows of the AACR Academy, while providing ongoing advice and counsel to the AACR leadership on timely and significant scientific and policy topics as well as other matters of importance to the cancer field.

The next elected class of Fellows of the AACR Academy will be formally recognized in conjunction with the AACR Annual Meeting 2021 Opening Ceremony.

AACR SCIENTIFIC ACHIEVEMENT AWARDS, LECTURESHIPS, AND PRIZES

In 1961, the AACR established its first scientific achievement award, partnering with Eli Lilly and Company to present the AACR G.H.A. Clowes Memorial Award. Named for G.H.A. Clowes, a founding member of the AACR and a past research director at Eli Lilly and Company, the award was created to recognize an individual scientist for outstanding recent accomplishments in the field of basic cancer research.

More than fifty years later, the AACR continues to recognize and reward scientific excellence in all areas of cancer research by annually administering 19 different scientific achievement awards and lectureships. In addition to these awards, the AACR annually presents the AACR June L. Biedler Prize for Cancer Journalism, which since 2015 has recognized outstanding journalistic coverage that enhances the general public’s understanding of cancer science and medicine.

All 2020-2021 AACR awardees will be formally recognized throughout the AACR Annual Meeting 2021, with the majority of individuals presenting featured scientific lectures highlighting their research accomplishments. We encourage you to attend these lectures and also to nominate your colleagues for one or more of these prestigious awards at AACR.org/Awards.
VIRTUAL SATELLITE EDUCATIONAL SYMPOSIA

Virtual Satellite Educational Symposia will be held in conjunction with the AACR Annual Meeting. These CME-accredited events are supported by parties other than AACR and are not part of the official program of the AACR Annual Meeting. Symposia are evaluated by the Satellite Educational Symposia Committee to ensure that the educational content will enhance that provided by the official AACR scientific program. Additional information will be available at AACR.org/AACR2021.

VIRTUAL EXHIBIT SHOW

The 2021 AACR Virtual Exhibit Show will include a wide array of companies with the latest products and services for laboratory and clinical research. If your organization would like to exhibit and would like to receive an Exhibitor Prospectus, please contact the Exhibits Team at 215-440-9300 or by email at exhibits@aacr.org.

“Exceptional during this unexpected hard time.”

AACR VIRTUAL ANNUAL MEETINGS I AND II 2020
AACR ANNUAL MEETING 2021
COMMITTEES

AACR ANNUAL MEETING PROGRAM COMMITTEE

Chair
Charles Swanton

Vice Chairs
Lewis C. Cantley
Heather R. Christofk
Melissa B. Davis
Keith T. Flaherty
Ricky W. Johnstone
Karen E. Knudsen
Quynh-Thu Le
Jean-Charles Soria
Louis M. Staudt
David A. Tuveson

Co-chairs
Peter C. Adamson
Carole L. Baas
Dafna Bar-Sagi
David L. Bartlett
Julie R. Brahmer
Javier Cortés
Riccardo Dalla-Favera
Luis A. Diaz
John F. DiPersio
Steven M. Dubinett
Tariq Enver
Douglas T. Fearon
Irene M. Ghobrial
Anna R. Giuliano
W. Nicholas Haining
James R. Heath
Manuel Hidalgo
Melissa M. Hudson
Stephen D. Hursting
Christine A. Iacobuzio-Donahue
Roger S. Lo
Elli Papaemmanuil
David Pellman
Erik Sahai
Stephen P. Schoenberger
Shelley S. Tworoger
Roel Verhaak
Jane E. Visvader

AACR EDUCATION COMMITTEE

Chair
Roger S. Lo

Additional Appointments Pending

AACR CLINICAL TRIALS COMMITTEE

Co-chairs
Julie R. Brahmer
Manuel Hidalgo

Members
Stephen B. Baylin
Joseph N. Contessa
Johann S. de Bono
Stephan A. Grupp
Susan Halabi
Matthew D. Hellmann
Corey J. Langer
Malcolm J. Moore
Kunle Odunsi
Pamela S. Ohashi
Suresh S. Ramalingam
Russell J. Schilder
Yu Shyr
Mark A. Socinski
Roger Stupp
Weijing Sun
Charles Swanton
Dan Theodorescu
Brian Andrew Van Tine
Ignacio I. Wistuba
Stephen Yip

Additional Appointments Pending